Literature DB >> 12130924

Retroperitoneal sarcomas: combined modality treatment approaches.

Peter W T Pisters1, Brian O'Sullivan.   

Abstract

Retroperitoneal soft tissue sarcomas are rare tumors estimated to account for 15%of all patients with soft tissue sarcoma seen in referral populations. The standard of care for patients with localized, resectable retroperitoneal sarcomas is surgical resection with gross and microscopically negative margins. However, owing to the large size and locally advanced nature of these tumors, this goal is difficult to achieve in most patients. As a result, the disease is characterized by a high propensity for local recurrence and a grade-specific risk for distant metastasis. Over the past decade, there has been considerable research into combined modality treatment of these tumors. The present report outlines current concepts relating to the diagnosis, staging, and management of retroperitoneal sarcomas. Emphasis is placed on evolving combined modality treatment approaches and current investigational strategies.

Entities:  

Mesh:

Year:  2002        PMID: 12130924     DOI: 10.1097/00001622-200207000-00006

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  16 in total

Review 1.  Recent advances in radiotherapy for soft-tissue sarcoma.

Authors:  Brian O'Sullivan; Iain Ward; Charles Catton
Journal:  Curr Oncol Rep       Date:  2003-07       Impact factor: 5.075

2.  [Therapeutic management of intra-abdominal and retroperitoneal soft tissue sarcomas].

Authors:  S Wong; M F Brennan
Journal:  Chirurg       Date:  2004-12       Impact factor: 0.955

3.  Retroperitoneal sarcomas- a challenging problem.

Authors:  Vijay Kumar; Sanjeev Misra; Arun Chaturvedi
Journal:  Indian J Surg Oncol       Date:  2012-05-30

4.  Curved incision under the costal margin in retroperitoneal tumor surgery.

Authors:  Yang Qin; Yong Yang; Hong Yang; Jun Li
Journal:  Mol Clin Oncol       Date:  2015-04-08

5.  Acute haemorrhage from a retroperitoneal liposarcoma: a rare presentation.

Authors:  Mohammed Al Sheikh; Nick Simson; Obinna Obi-Njoku; Ahmed Qteishat
Journal:  BMJ Case Rep       Date:  2018-02-08

6.  CT perfusion as an imaging biomarker in monitoring response to neoadjuvant bevacizumab and radiation in soft-tissue sarcomas: comparison with tumor morphology, circulating and tumor biomarkers, and gene expression.

Authors:  Avinash Kambadakone; Sam S Yoon; Tae-Min Kim; Daniel L Karl; Dan G Duda; Thomas F DeLaney; Dushyant V Sahani
Journal:  AJR Am J Roentgenol       Date:  2015-01       Impact factor: 3.959

7.  Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas.

Authors:  Sam S Yoon; Dan G Duda; Daniel L Karl; Tae-Min Kim; Avinash R Kambadakone; Yen-Lin Chen; Courtney Rothrock; Andrew E Rosenberg; G Petur Nielsen; David G Kirsch; Edwin Choy; David C Harmon; Francis J Hornicek; Jonathan Dreyfuss; Marek Ancukiewicz; Dushyant V Sahani; Peter J Park; Rakesh K Jain; Thomas F Delaney
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-06       Impact factor: 7.038

8.  Accuracy of preoperative percutaneous biopsy for the diagnosis of retroperitoneal liposarcoma subtypes.

Authors:  Naruhiko Ikoma; Keila E Torres; Neeta Somaiah; Kelly K Hunt; Janice N Cormier; William Tseng; Dina Lev; Raphael Pollock; Wei Lien Wang; Barry Feig
Journal:  Ann Surg Oncol       Date:  2014-10-30       Impact factor: 5.344

9.  Retroperitoneal soft tissue sarcomas: experience at a single institution in Mexico.

Authors:  Luis García-Aceituno; Cynthia Villarreal-Garza; Miguel Perfecto; Eucario León-Rodríguez
Journal:  World J Surg       Date:  2010-07       Impact factor: 3.352

10.  Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1α.

Authors:  Yeo-Jung Kim; Hae-June Lee; Tae-Min Kim; T S Karin Eisinger-Mathason; Alexia Y Zhang; Benjamin Schmidt; Daniel L Karl; Michael S Nakazawa; Peter J Park; M Celeste Simon; Sam S Yoon
Journal:  Int J Cancer       Date:  2012-06-26       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.